VRTX241220C590000
- 0.15
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $550 From $570, Maintains Buy Rating
Bernstein Adjusts Vertex Pharmaceuticals Price Target to $441 From $506, Maintains Market Perform Rating
Barclays Adjusts Vertex Pharmaceuticals Price Target to $418 From $509, Maintains Equalweight Rating
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Price Target Cut to $535.00/Share From $600.00 by HC Wainwright & Co.
Vertex Downgraded to Perform by Oppenheimer
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
RBC Capital Cuts Vertex Pharmaceuticals' Price Target to $400 From $451
Wolfe Research Cuts Vertex Pharmaceuticals' Price Target to $531 From $538
BMO Capital Cuts Price Target on Vertex Pharmaceuticals to $520 From $566
Vertex Pharmaceuticals Analyst Ratings
Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $494
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $494 From $490, Maintains Hold Rating
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings